There are no approved vaccines for the disease from the coronavirus, which has so far infected some 12,721,778 people and killed 565,189 worldwide, according to Johns Hopkins University, Press TV reported on Sunday.
Vadim Tarasov, the director of the Russian Institute for Transnational Medicine and Biotechnology, said the clinical trials of a potential vaccine had been successfully completed on volunteers at the Sechenov First Moscow State Medical University.
He said the first group of volunteers would be discharged on Wednesday.
According to the director of the Institute of Medical Parasitology, Tropical, and Vector-Borne Diseases at the university, the objective of that stage of the study was to show the vaccine’s safety on humans.
“The safety of the vaccine has been confirmed. It corresponds to the safety of those vaccines that are currently on the market,” Alexander Lukashev said.
Russia, with 727,162 confirmed cases of COVID-19, is the world’s fourth-worst-hit country. It has also recorded 11,335 related deaths so far.
Meanwhile, a Chinese vaccine developer said it was in talks with Russia, Brazil, Chile, and Saudi Arabia to launch the phase three of the trials of a vaccine on human beings.
“We are contacting Russia, Brazil, Chile, and Saudi Arabia, and it’s still in discussion,” said Qiu Dongxu, the executive director and cofounder of CanSino Biologics.
Qiu told a conference in Suzhou, in eastern China, that the phase III trial was likely to start “pretty soon,” and that the company planned to recruit 40,000 participants for the test.
He said its new factory under construction in China will allow it to produce 100-200 million doses of coronavirus vaccines per year by early 2021.
China, the first ever nation to report the coronavirus infection, has so far reported more than 85,000 cases and over 4,600 fatalities.
Researchers in Thailand also plan to begin human trials of a potential vaccine for the disease in November, according to Kiat Ruxrungtham, the director of Bangkok’s Chulalongkorn University vaccine development program.
Kiat said on Sunday that following favorable results in trials on primates, the next step was to manufacture doses for human trials.
“If everything goes according to plan, the vaccine will be ready for Thailand in the third or fourth quarter next year,” he said.
Thailand on Sunday had a total of 3,217 confirmed infections, with no local transmissions reported in over a month, and 58 COVID-19 deaths.
No local transmission has been reported in the county for over a month.